Sucampo Pharmaceuticals, Inc. Completes Enrollment in Phase 3 Pivotal Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction

BETHESDA, MD--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that it has completed enrollment and initial dosing of patients in two pivotal phase 3 trials of lubiprostone for the treatment of Opioid-Induced Bowel Dysfunction (OBD).